Plaster which sticks inside the mouth will revolutionise treatment of oral conditions

A plaster which sticks to the inside of your mouth is revolutionizing the treatment of painful recurring ulcers.

The biodegradable patch sticks inside the mouth and helps to accelerate the treatment of painful ulcers CREDIT University of Sheffield
The biodegradable patch sticks inside the mouth and helps to accelerate the treatment of painful ulcers CREDIT University of Sheffield

Researchers from the University of Sheffield‘s School of Clinical Dentistry, working in a close coordinated effort with Dermtreat A/S from Copenhagen, have built up an interesting patch utilizing uncommon polymers which can stick to wet surfaces.

The patch effectively regulates steroids specifically to oral ulcers or lesions while additionally making a protective barrier around the influenced zone, quickening the healing procedure.

The novel plaster is a leap forward treatment for the treatment of mucosal conditions, for example, oral lichen planus (OLP) and repetitive aphthous stomatitis (RAS), which are infections that reason excruciating injuries and influence 1-2 percent of the populace.

The biodegradable Rivelin® patch has a long adhesion time and a high flexibility which conforms to the surface inside the mouth.

Dr. Craig Murdoch, Reader in Oral Bioscience School of Clinical Dentistry and lead author of the research, said: “Chronic inflammatory conditions such as OLP and RAS, which cause erosive and painful oral lesions, have a considerable impact on quality of life.

“Current treatments consist of using steroids in the form of mouthwashes, creams or ointments, but these are often ineffective due to inadequate drug contact times with the lesion.

“The patch acts like a plaster inside your mouth, which means it is very effective at directly targeting the specific area as well as forming a protective barrier.

“Patients who have trialed the patch found it to be very comfortable to wear and they were really pleased with the length of adhesion which makes it particularly effective and efficient.”

Jens Hansen, Chief Executive Officer at Dermtreat A/S, added: “Collaboration with the University of Sheffield has undoubtedly accelerated the translation of our intellectual property towards clinical use. Our company is very confident that we will soon gain regulatory approval for the first adhesive drug delivery technology to address pressing clinical needs in oral medicine.

“We look forward to continuing this collaboration, which will be increasingly directed at finding new clinical applications for mucoadhesive patches.”

The findings of the research are published in the journal Biomaterials.